Dr Reddy’s launches naloxone hydrochloride injection in US

Our Bureau Hyderabad | Updated on March 19, 2020

Dr Reddy’s Laboratories Ltd has launched naloxone hydrochloride injection pre-filled syringes in the US market.

The launched product is a therapeutic equivalent generic version of Narcan injection approved by the USFDA.

“We are pleased to bring our second product to market that has been designated as a competitive generic therapy (CGT) by the USFDA,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories, said in a release. “With a CGT designation, we have 180-day CGT exclusivity to market this product.”

Naloxone hydrochloride injections had US sales of approximately $31 million for the 12 months ended January 2020, according to IQVIA Health data.

Dr Reddy’s naloxone hydrochloride injection is available in 2 mL single-dose prefilled syringes.

Published on March 19, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor